New options for cilostazol-based dual antiplatelet therapy for ischaemic stroke prevention in East Asian populations: a systematic review and meta-analysis.

ABSTRACT:

Background and purpose

The objective of this study is to systematically review the efficacy and safety of cilostazol-based dual antiplatelet therapy (DAPT) in patients with stroke.

Methods

Two reviewers conducted a comprehensive search of eligible studies published in PubMed, Medline, the Cochrane Library, Embase, and four Chinese databases from their establishment to 31 July 2024. The review was registered (CRD42024559047).

Results

This study included a total of 4,473 subjects from 11 studies. The results indicated that, when compared to aspirin/clopidogrel single antiplatelet therapy (SAPT), cilostazol-based DAPT was associated with lower ischemic stroke (RR = 0.54, 95% CI 0.38-0.75, P = 0.0003) and any stroke recurrence (RR = 0.52, 95% CI 0.31-0.86, P

SUBMITTER: Wang X 

PROVIDER: S-EPMC11880014 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature